Katherine M. Hannan

This paper identifies a synergistic combination of RNA Polymerase I inhibitor CX-5461 and CDK inhibitor Dinaciclib that enhances therapeutic efficacy in AML by inducing nucleolar stress and cell cycle arrest.

This study shows PMR-116, a second-generation RiBi inhibitor, effectively targets high-MYC cancers without causing DNA damage, suggesting RiBi as a viable cancer therapy.

The paper introduces a method to estimate rDNA copy number using modal coverage and applies it to yeast isolates, finding population-level variation in copy numbers.

The paper identifies a shift in the active miRNA targetome in a mouse model of retinal degeneration, showing changes in miRNA binding regions and AGO2 localization.